Greg Verdine, LifeMine CEO (via Harvard)
March 23, 2022 06:30 AM EDTUpdated 09:39 AM
Financing
Startups
Deals

Greg Ver­dine will have many new C-suite friends at fun­gus biotech LifeM­ine af­ter GSK-fu­eled $175M round

Kyle LaHucik

Senior Reporter

A year af­ter se­cur­ing funds from Rick Klaus­ner and adding No­bel lau­re­ate William Kaelin to the board, fun­gus-fo­cused LifeM­ine Ther­a­peu­tics is ready to re­veal …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

From vac­cines to psy­che­delics, five drug­mak­ers on what could change un­der a Trump ad­min­is­tra­tion

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times